Robert L. Kunka - Concepedia

Author

Robert L. Kunka

Research Triangle Park Foundation

Also Known As

R Kunka, R L Kunka, R. Kunka, R.L. Kunka, Robert L Kunka, Robert L. Kunka

Publications

564

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation University of Pittsburgh Magee-Womens Hospital GlaxoSmithKline (United States)

About

Robert L. Kunka is an author at Research Triangle Park Foundation specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	404
2	Allergy	2	2	107
3	Allergy Medicine	2	2	107
4	Natural Sciences	1	1	27
5	Biochemistry	1	1	27

Robert L. Kunka

Publications

545

Citations

H-Index

Page 1

	Year	Citations
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays Peter T. Daley‐Yates, Robert L. Kunka, Yongguang Yin, European Journal of Clinical Pharmacology AllergyAllergy MedicineMedicineAllergenFluticasone Propionate	2004	76
Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses P. J. Morrison, Tim Mant, G T Norman, Antimicrobial Agents and Chemotherapy Pharmacological StudyDrug CrystalsDose LevelsElimination Half-lifePharmacology	1988	75
Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. Thomas R. Spitzer, Judy C. Bryson, E Cirenza, Journal of Clinical Oncology	1994	54
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration CJH Gerrits, G.J. Creemers, JHM Schellens, British Journal of Cancer Intravenous AdministrationNew TopoisomeraseMedicinePharmacotherapyAnti-cancer Agent	1996	45
An Automated Method for the Determination of Montelukast in Human Plasma Using Dual-Column HPLC Analysis and Peak Height Summation of the Parent Compound and Its Photodegradation Product Glenn Smith, Cynthia M. Rawls, Robert L. Kunka Pharmaceutical Research Photodegradation ProductGas ChromatographyMedicineMass SpectrometryAutomated Method	2004	40
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. S. Gail Eckhardt, Sharyn D. Baker, John R. Eckardt, PubMed Pharmacokinetic StudyPathologyPharmacotherapyObserved LactoneConsecutive Days	1998	36
Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs Robert L. Kunka, Susan Andrews, M. Pimazzoni, Respiratory Medicine Dose ProportionalityMedicineInhalation ToxicologyFluorous SynthesisFluticasone Propionate	2000	32
Comparison of the Systemic Availability of Fluticasone Propionate in Healthy Volunteers and Patients with Asthma Peter T. Daley‐Yates, Julien Tournant, Robert L. Kunka Clinical Pharmacokinetics AsthmaAllergyAllergy MedicineHealthy VolunteersImmunology	2000	31
Factors affecting the plasma protein binding of verapamil and norverapamil in man. Candice Yong, Robert L. Kunka, Theodore R. Bates PubMed Medicinal ChemistryVivo BindingPharmacological StudyBiochemistryMedicine	1980	27
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion Luis Paz‐Ares, Robert L. Kunka, D Demaria, British Journal of Cancer MedicinePharmacokinetic StudyClinical PharmacologyPharmacotherapy72-H Continuous Infusion	1998	23

Page 1